In this article, we are going to take a look at where ALX Oncology Holdings Inc. (NASDAQ:ALXO) stands against the other stocks. The stock market pulled back to the red territory on Thursday ...

Cassie has been doing just fine with Alex Fine since splitting from Sean “Diddy” Combs. Shortly after the “Me & U” singer’s on-again, off-again romance with the record executive came to ...

ALX Oncology (ALXO) will highlight progress across its clinical pipeline, including continued advancement of investigational CD47-blocker evorpacept and planned entry into the clinic of its novel ...

(RTTNews) - ALX Oncology Holdings Inc. (ALXO), a biopharmaceutical company focused on oncology treatments, has announced a workforce reduction of approximately 30% as part of its strategy to ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

ALX Oncology stock opened at $1.03 on Tuesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. ALX Oncology has a 52 week low of $0.96 and a 52 ...

ALX Oncology announced promising results from the ASPEN-06 Phase 2 clinical trial of its CD47-blocker, evorpacept, at the 2025 ASCO Gastrointestinal Cancers Symposium. This investigational ...

Fresh from a $105 million third-round financing earlier this month, ALX Oncology has won two FDA fast-track designations for its lead immuno-oncology drug. The Irish-American biotech picked up the ...